135 related articles for article (PubMed ID: 7216469)
1. Dengue-2 vaccine: virological, immunological, and clinical responses of six yellow fever-immune recipients.
Bancroft WH; Top FH; Eckels KH; Anderson JH; McCown JM; Russell PK
Infect Immun; 1981 Feb; 31(2):698-703. PubMed ID: 7216469
[TBL] [Abstract][Full Text] [Related]
2. Dengue 2 vaccine: dose response in volunteers in relation to yellow fever immune status.
Scott RM; Eckels KH; Bancroft WH; Summers PL; McCown JM; Anderson JH; Russell PK
J Infect Dis; 1983 Dec; 148(6):1055-60. PubMed ID: 6655288
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers.
Kanesa-thasan N; Sun W; Kim-Ahn G; Van Albert S; Putnak JR; King A; Raengsakulsrach B; Christ-Schmidt H; Gilson K; Zahradnik JM; Vaughn DW; Innis BL; Saluzzo JF; Hoke CH
Vaccine; 2001 Apr; 19(23-24):3179-88. PubMed ID: 11312014
[TBL] [Abstract][Full Text] [Related]
4. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates.
Guirakhoo F; Weltzin R; Chambers TJ; Zhang ZX; Soike K; Ratterree M; Arroyo J; Georgakopoulos K; Catalan J; Monath TP
J Virol; 2000 Jun; 74(12):5477-85. PubMed ID: 10823852
[TBL] [Abstract][Full Text] [Related]
5. Atypical antibody responses in dengue vaccine recipients.
Kanesa-Thasan N; Sun W; Ludwig GV; Rossi C; Putnak JR; Mangiafico JA; Innis BL; Edelman R
Am J Trop Med Hyg; 2003 Dec; 69(6 Suppl):32-8. PubMed ID: 14740953
[TBL] [Abstract][Full Text] [Related]
6. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection.
Reinhardt B; Jaspert R; Niedrig M; Kostner C; L'age-Stehr J
J Med Virol; 1998 Oct; 56(2):159-67. PubMed ID: 9746073
[TBL] [Abstract][Full Text] [Related]
7. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.
Guirakhoo F; Kitchener S; Morrison D; Forrat R; McCarthy K; Nichols R; Yoksan S; Duan X; Ermak TH; Kanesa-Thasan N; Bedford P; Lang J; Quentin-Millet MJ; Monath TP
Hum Vaccin; 2006; 2(2):60-7. PubMed ID: 17012873
[TBL] [Abstract][Full Text] [Related]
8. Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. V. Human response to immunization with a candidate vaccine prepared in fetal rhesus lung cells.
Eckels KH; Scott RM; Bancroft WH; Brown J; Dubois DR; Summers PL; Russell PK; Halstead SB
Am J Trop Med Hyg; 1984 Jul; 33(4):684-9. PubMed ID: 6476216
[TBL] [Abstract][Full Text] [Related]
9. Dengue virus type 2 vaccine: reactogenicity and immunogenicity in soldiers.
Bancroft WH; Scott RM; Eckels KH; Hoke CH; Simms TE; Jesrani KD; Summers PL; Dubois DR; Tsoulos D; Russell PK
J Infect Dis; 1984 Jun; 149(6):1005-10. PubMed ID: 6376649
[TBL] [Abstract][Full Text] [Related]
10. Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers.
Vaughn DW; Hoke CH; Yoksan S; LaChance R; Innis BL; Rice RM; Bhamarapravati N
Vaccine; 1996 Mar; 14(4):329-36. PubMed ID: 8744561
[TBL] [Abstract][Full Text] [Related]
11. Preparation of an attenuated dengue 4 (341750 Carib) virus vaccine. II. Safety and immunogenicity in humans.
Hoke CH; Malinoski FJ; Eckels KH; Scott RM; Dubois DR; Summers PL; Simms T; Burrous J; Hasty SE; Bancroft WH
Am J Trop Med Hyg; 1990 Aug; 43(2):219-26. PubMed ID: 2389825
[TBL] [Abstract][Full Text] [Related]
12. In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination.
Whitehead SS; Durbin AP; Pierce KK; Elwood D; McElvany BD; Fraser EA; Carmolli MP; Tibery CM; Hynes NA; Jo M; Lovchik JM; Larsson CJ; Doty EA; Dickson DM; Luke CJ; Subbarao K; Diehl SA; Kirkpatrick BD
PLoS Negl Trop Dis; 2017 May; 11(5):e0005584. PubMed ID: 28481883
[TBL] [Abstract][Full Text] [Related]
13. rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers.
Durbin AP; Whitehead SS; McArthur J; Perreault JR; Blaney JE; Thumar B; Murphy BR; Karron RA
J Infect Dis; 2005 Mar; 191(5):710-8. PubMed ID: 15688284
[TBL] [Abstract][Full Text] [Related]
14. Tick-borne Langat/mosquito-borne dengue flavivirus chimera, a candidate live attenuated vaccine for protection against disease caused by members of the tick-borne encephalitis virus complex: evaluation in rhesus monkeys and in mosquitoes.
Pletnev AG; Bray M; Hanley KA; Speicher J; Elkins R
J Virol; 2001 Sep; 75(17):8259-67. PubMed ID: 11483771
[TBL] [Abstract][Full Text] [Related]
15. A live attenuated dengue-1 vaccine candidate (45AZ5) passaged in primary dog kidney cell culture is attenuated and immunogenic for humans.
Edelman R; Tacket CO; Wasserman SS; Vaughn DW; Eckels KH; Dubois DR; Summers PL; Hoke CH
J Infect Dis; 1994 Dec; 170(6):1448-55. PubMed ID: 7995984
[TBL] [Abstract][Full Text] [Related]
16. Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination.
Nivarthi UK; Kose N; Sapparapu G; Widman D; Gallichotte E; Pfaff JM; Doranz BJ; Weiskopf D; Sette A; Durbin AP; Whitehead SS; Baric R; Crowe JE; de Silva AM
J Virol; 2017 Mar; 91(5):. PubMed ID: 28031369
[TBL] [Abstract][Full Text] [Related]
17. Antibody response to dengue-2 vaccine measured by two different radioimmunoassay methods.
Summers PL; Eckels KH; Dalrymple JM; Scott RM; Boyd VA
J Clin Microbiol; 1984 May; 19(5):651-9. PubMed ID: 6330164
[TBL] [Abstract][Full Text] [Related]
18. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region.
Durbin AP; Karron RA; Sun W; Vaughn DW; Reynolds MJ; Perreault JR; Thumar B; Men R; Lai CJ; Elkins WR; Chanock RM; Murphy BR; Whitehead SS
Am J Trop Med Hyg; 2001 Nov; 65(5):405-13. PubMed ID: 11716091
[TBL] [Abstract][Full Text] [Related]
19. Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53): clinical, immunological and biological responses in adult volunteers.
Bhamarapravati N; Yoksan S; Chayaniyayothin T; Angsubphakorn S; Bunyaratvej A
Bull World Health Organ; 1987; 65(2):189-95. PubMed ID: 3496985
[TBL] [Abstract][Full Text] [Related]
20. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates.
Monath TP; Soike K; Levenbook I; Zhang ZX; Arroyo J; Delagrave S; Myers G; Barrett AD; Shope RE; Ratterree M; Chambers TJ; Guirakhoo F
Vaccine; 1999 Apr; 17(15-16):1869-82. PubMed ID: 10217584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
